Ahmed M. Shehata

Ahmed M. Shehata

Auto-generated profile, based on publicly available information

Ahmed M. Shehata

Department of Pharmacology, Institute of Pharmaceutical Sciences, University of Tübingen, Tübingen, Germany

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in International Journal of Nanomedicine
Verified
Journal Article
Open access
AAAmit Alexander
Amit Alexander
MAMukta Agrawal
Mukta Agrawal
AUAjaz Uddin
Ajaz Uddin
SSSabahuddin Siddique
Sabahuddin Siddique
ASAhmed M Shehata
Ahmed M Shehata
Mohamed ShakerMohamed Shaker
Mohamed Shaker
The treatment of central nervous system (CNS) disorders always remains a challenge for the researchers. The presence of various physiological barriers, primarily the blood-brain barrier (BBB) limits the accessibility of the brain and hinders the efficacy of various drug therapies. Hence, drug targeting to the brain, particularly to the diseased cells by circumventing the physiological barriers is essential to develop a promising therapy for the treatment of brain disorders. Presently, the investigations emphasize the role of different nanocarrier systems or surface modified target specific novel carrier system to improve the efficiency and reduce the side effects of the brain therapeutics. Such approaches supposed to circumvent the BBB or have the ability to cross the barrier function and thus increases the drug concentration in the brain. Although the efficacy of novel carrier system depends upon various physiological factors like active efflux transport, protein corona of the brain, stability, and toxicity of the nanocarrier, physicochemical properties, patient-related factors and many more. Hence, to develop a promising carrier system, it is essential to understand the physiology of the brain and BBB and also the other associated factors. Along with this, some alternative route like direct nose-to-brain drug delivery can also offer a better means to access the brain without exposure of the BBB. In this review, we have discussed the role of various physiological barriers including the BBB and blood-cerebrospinal fluid barrier (BCSFB) on the drug therapy and the mechanism of drug transport across the BBB. Further, we discussed different novel strategies for brain targeting of drug including, polymeric nanoparticles, lipidic nanoparticles, inorganic nanoparticles, liposomes, nanogels, nanoemulsions, dendrimers, quantum dots, etc. along with the intranasal drug delivery to the brain. We have also illustrated various factors affecting the drug targeting efficiency of the developed novel carrier system.

1 September 2011 in Phytomedicine
Verified
Journal Article
Closed access
ASAhmed M. Shehata
Ahmed M. Shehata
LQL. Quintanilla-Fend
L. Quintanilla-Fend
SBSabrina Bettio
Sabrina Bettio
CSC.B. Singh
C.B. Singh
HAH.P.T. Ammon
H.P.T. Ammon

1 February 2018 in Bioorganic Chemistry
Verified
Journal Article
Closed access
HAHany E. A. Ahmed
Hany E. A. Ahmed
SISaleh K. Ihmaid
Saleh K. Ihmaid
Abdelsattar Mansour Ebeif OmarAbdelsattar Mansour Ebeif Omar
Abdelsattar Mansour Ebeif Omar
ASAhmed M. Shehata
Ahmed M. Shehata
HRHeba Rateb
Heba Rateb
MEMahmoud M. Elaasser
Mahmoud M. Elaasser

7 May 2015 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
PDF file
ASA. M. Shehata
A. M. Shehata
LQL. Quintanilla-Fend
L. Quintanilla-Fend
SBS. Bettio
S. Bettio
JJJ. Jauch
J. Jauch
TSThomas Scior
Thomas Scior
HAH. P. T. Ammon
H. P. T. Ammon
The aim of the work was to study whether or not 11-keto-β-boswellic acids prevent induction of autoimmune reactions, insulitis, and hyperglycemia in the model of multiple low-dose streptozotocin (MLD-STZ) diabetes. Using male mice (n=6) diabetes was induced by daily i.p. injections of 40 mg/kg STZ for 5 days. In a second series together with STZ, daily i. p. injections of 11-keto-β-boswellic acid (KBA) and O-acetyl-11-keto-β-boswellic acid (AKBA) (7.5 and 15.0 mg/kg) were applied for 10 days. Thereafter, pro-and anti-inflammatory cytokines in the blood, histochemistry of pancreatic islets, and blood glucose levels were assayed. Five days after the last injection of STZ, a significant burst of pro-and anti-inflammatory cytokines in the blood, infiltration of lymphocytes (CD3) into pancreatic islets, and appearance of peri-insular apoptotic cells were observed. Plasma glucose increased significantly (124.4±6.65 vs. 240.2±27.36 mg/dl, p<0.05). Simultaneous treatment with KBA and AKBA significantly reduced pro-and anti-inflammatory cytokines (IFN-γ p<0.01, p<0.01; IL-1A p<0.001, p<0.001; IL-1B p<0.001, p<0.001; IL-2 p<0.001, p<0.001; IL-6 p<0.01, p<0.001; TNF-α p<0.05, p<0.001; IL-4 p<0.01, p<0.001; IL-10 p<0.001, p<0.001) in the blood. No infiltration of lymphocytes into pancreatic islets and appearance of peri-insular cells were detected. Moreover, KBA and AKBA reduced STZ-mediated increase of blood glucose on day 10 to 163.25±16.6 (p<0.05) and 187.6±19.5 mg/dl (p<0.05), respectively. In the model of MLD-STZ induced diabetes KBA and AKBA prevent cytokine burst, development of insulitis and reduce increase of blood glucose through “silencing” a forced-up immune reaction.

31 July 2017 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
PDF file
ASAhmed M. Shehata
Ahmed M. Shehata
LQLeticia Quintanilla-Fend
Leticia Quintanilla-Fend
SBSabrina Bettio
Sabrina Bettio
ZKZahra Kamyabi-Moghaddam
Zahra Kamyabi-Moghaddam
UKUrsula A. Kohlhofer
Ursula A. Kohlhofer
HAH. P. T. Ammon
H. P. T. Ammon
11-Keto-β-Boswellic acid (KBA) has been shown to prevent infiltration of lymphocytes into pancreatic islets and appearance of peri-insular apoptotic cells in an animal model of autoimmune diabetes caused by injection of Multiple Low Doses of Streptozotocin (MLD-STZ), which is a chemical compound belonging to the class of nitrososureas. The aim of this work was to study whether or not KBA can also prevent/attenuate infiltration of lymphocytes into pancreatic islets and appearance of peri-insular apoptotic cells in an animal model of autoimmune diabetes caused by genetic dysfunction resembling human type 1 diabetes in several important features. Four weeks old female NOD mice received daily i.p. injections of 7.5 mg/kg of KBA over a period of 3 weeks. Compared to 4 weeks old animals there was significant infiltration of lymphocytes (CD3) into pancreatic islets and appearance of peri-insular apoptotic cells in the period between 4 and 7 weeks. During this time plasma glucose dropped significantly and body weight did not increase. As far as pro-inflammatory cytokines are concerned, except a small increase of IFN-γ, there was no change in the blood. In mice that had been treated with KBA between 4 and 7 weeks after birth no significant infiltration of lymphocytes into pancreatic islets and appearance of peri-insular apoptotic cells was observed, when compared to 4 weeks old mice. Moreover, there was no drop of blood glucose and the animals gained body weight. It is concluded that – similar to the model of MLD-STZ-diabetes – also in the NOD mouse model KBA is able to attenuate or even prevent development of insulitis, suggesting that KBA protects islets from autoimmune reaction regardless whether the signal is provided by a chemical compound or by genetic dysfunction. Whether this also holds for human type 1 diabetes remains to be established.

6 August 2022 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
SHShaimaa Mohamed Hassan
Shaimaa Mohamed Hassan
MAMoutasem S Aboonq
Moutasem S Aboonq
EAEmad A Albadawi
Emad A Albadawi
YAYasmeen Aljehani
Yasmeen Aljehani
HAHytham Mahmoud Abdel-Latif
Hytham Mahmoud Abdel-Latif
YEYasser M Elbastawisy
Yasser M Elbastawisy
Background: Studies regarding treatment of acute toxicity with diclofenac (ATD) are quite few. Diclofenac is commonly prescribed in neurology, psychiatry, and general medicine practice. This study investigated possible colon-protective effects exerted by Ajwa date fruit extract (ADFE), a prophetic medicine remedy native to Al-Madinah, Saudi Arabia against ATD. Phytochemicals in ADFE as gallic acid and quercetin have reported protective effects against ATD. Methods: Total phenols and flavonoids in ADFE were estimated as equivalents to gallic acid and quercetin. Four experimental groups were allocated each of six rats: control group, ATD group received a single dose of 150 mg diclofenac intraperitoneally, toxicity prevention group received a single dose of ADFE orally followed 4 hours later by diclofenac injection, and toxicity treatment group received a similar diclofenac dose followed 4 hours later by a single dose of ADFE. Four days later, animals were sacrificed. Histological and biochemical examinations were done. Results: ADFE has a total phenolic content of 331.7 gallic acid equivalent/gram extract and a total flavonoid content of 70.23 quercetin equivalent/gram. ATD significantly increased oxidative stress markers as serum malondialdehyde (MDA) and hydrogen peroxide (H2O2). Serum MDA and H2O2 were significantly scavenged by ADFE. ATD significantly (p< 0.001) decreased antioxidant power as serum total antioxidant capacity and catalase activity. That was reversed by ADFE in both prevention and treatment groups. Histologically, ATD caused complete destruction of colonic crypts architecture, patchy loss of the crypts, loss of the surface epithelium, absent goblet cells and submucosal exudate, heavy infiltration of the lamina propria and submucosa with inflammatory cells, mainly lymphocytes and eosinophils. There were mucosal haemorrhages and submucosal dilated congested blood vessels. All that was prevented and treated using ADFE. Conclusion: ADFE is rich in quercetin and gallic acid equivalents that exert potent antitoxic effects. ADFE is strongly recommended for preventive and therapeutic colon effects against ATD.